Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Auvinen, M. I.
Right arrow Articles by Salo, J. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Auvinen, M. I.
Right arrow Articles by Salo, J. A.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?
Journal of Clinical Oncology, Vol 20, Issue 13 (July), 2002: 2971-2979
© 2002 American Society for Clinical Oncology

Incipient Angiogenesis in Barrett’s Epithelium and Lymphangiogenesis in Barrett’s Adenocarcinoma

By Merja I. Auvinen, Eero I.T. Sihvo, Terhi Ruohtula, Jukka T. Salminen, Aki Koivistoinen, Päivi Siivola, Ragna Rönnholm, Juhani O. Rämö, Mathias Bergman, Jarmo A. Salo

From the Cellular Signalling Group, Division of Biochemistry, Department of Biosciences, Viikki BioCenter, University of Helsinki; and Department of Cardiothoracic Surgery, Helsinki University Central Hospital; and Karyon Ltd, Viiki BioCenter, Helsinki, Finland.

Address reprint requests to: Merja Auvinen, PhD, Division of Biochemistry, Department of Biosciences, Viikinkaari 5D, P.O. Box 56, Viikki BioCenter, FIN-00014 University of Helsinki, Finland; email: merja.auvinen{at}astrazeneca.com

PURPOSE: Barrett’s esophagus (BE), a precancerous condition for Barrett’s adenocarcinoma, is classically characterized by flames of salmon-colored mucosa extending into normal pale esophageal mucosa. This flaming is thought to be a consequence of continuous erosis of mucosa caused by chronic reflux. Another characteristic feature of Barrett’s adenocarcinoma patients is the frequent development of lymph node metastases. We addressed whether onset of angiogenesis occurs in BE and if the lymphatic system might provide a route for Barrett’s adenocarcinoma cells to infiltrate regular lymph nodes.

PATIENTS AND METHODS: Fifteen surgically resected Barrett’s dysplasia or adenocarcinoma patients were included. Immunohistochemistry and a modified whole mount analysis were used.

RESULTS: The incipient angiogenesis originates from the pre-existing vascular network in the lamina propria and infiltrates Barrett’s epithelium, giving its ominous salmon-red color. Barrett’s epithelium–specific goblet cells express vascular endothelial growth factor (VEGF)-A. The immature blood vessels show a relative absence of smooth muscle actin (SMA)-positive mural cells and express VEGF receptor (VEGFR)-2 and matrix metalloproteinase (MMP)-9 on their exterior. Coexpression of VEGF-C and its receptor VEGFR-3 on lymphatic vessels is demonstrated.

CONCLUSION: BE is strongly neovascularized not eroded. This novel concept of a molecular mechanism of the origin of BE might emphasize why precancerous BE can give rise to the more cancerous dysplasia and Barrett’s adenocarcinoma stages. In addition, adenocarcinoma cells induce lymphangiogenesis. The new lymphangiogenic vessels might provide a systemic route for adenocarcinoma cells to invade circulation and induce lymph node metastasis.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
Am J Clin PatholHome page
R. S. Saad, J. L. Lindner, Y. Liu, and J. F. Silverman
Lymphangiogenesis in Esophageal Adenocarcinomas--Lymphatic Vessel Density as Prognostic Marker in Esophageal Adenocarcinoma
Am J Clin Pathol, January 1, 2009; 131(1): 92 - 98.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
R. Zhai, G. Liu, K. Asomaning, L. Su, M. H. Kulke, R. S. Heist, N. S. Nishioka, T. J. Lynch, J. C. Wain, X. Lin, et al.
Genetic polymorphisms of VEGF, interactions with cigarette smoking exposure and esophageal adenocarcinoma risk
Carcinogenesis, December 1, 2008; 29(12): 2330 - 2334.
[Abstract] [Full Text] [PDF]


Home page
The OncologistHome page
S. Ekman, M. Bergqvist, C.-H. Heldin, and J. Lennartsson
Activation of Growth Factor Receptors in Esophageal Cancer Implications for Therapy
Oncologist, October 1, 2007; 12(10): 1165 - 1177.
[Abstract] [Full Text] [PDF]


Home page
GutHome page
R C Fitzgerald
Molecular basis of Barrett's oesophagus and oesophageal adenocarcinoma.
Gut, December 1, 2006; 55(12): 1810 - 1820.
[Full Text] [PDF]


Home page
J. Clin. Pathol.Home page
M-A Brundler, J A Harrison, B de Saussure, M de Perrot, and M S Pepper
Lymphatic vessel density in the neoplastic progression of Barrett's oesophagus to adenocarcinoma
J. Clin. Pathol., February 1, 2006; 59(2): 191 - 195.
[Abstract] [Full Text] [PDF]


Home page
The OncologistHome page
W. P. Tew, D. P. Kelsen, and D. H. Ilson
Targeted Therapies for Esophageal Cancer
Oncologist, September 1, 2005; 10(8): 590 - 601.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Pathol.Home page
M. D. Basson
Gut Mucosal Healing : Is the Science Relevant?
Am. J. Pathol., October 1, 2002; 161(4): 1101 - 1105.
[Full Text] [PDF]



About
JCO
 Editorial
Roster
 Advertising
Information
 Librarians &
Institutions
 Rights &
Permissions
 PDA Services

Copyright © 2002 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online